Company Mateon Therapeutics, Inc. Other OTC
Equities
MATN
US57667K1097
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22/19/22 |
Director of Finance/CFO | 57 | 01/19/01 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 06/20/06 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 11/20/11 |
Saran Saund
PRN | Corporate Officer/Principal | 66 | 01/19/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Steven King
BRD | Director/Board Member | 59 | 11/20/11 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 11/20/11 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22/19/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 399,684,128 | 180,543,314 ( 45.17 %) | 0 | 45.17 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |